Rapid and functional evaluation of virus-neutralizing antibodies using multi-parametric live cell analysis
26 Aug 2020
Current methods for screening virus-neutralizing antibodies, including the canonical plaque reduction neutralization test, require multiple handling steps and numerous days to complete. This presentation will highlight a more efficient assay that identifies virus-neutralizing antibodies in real-time.
Using the principle of cellular impedance, the xCELLigence RTCA eSight simultaneously monitors virus-induced changes in cell number, cell size, cell-substrate attachment strength, and cell-cell adhesion. The eSight couples this real-time impedance data with live-cell imaging to provide a sensitive and information-rich interrogation of cytopathic effects that span the entire viral life cycle. Beyond antibody screening, eSight assay design and quantitative evaluation of antibody efficacy by IC50s will also be discussed. Finally, it will be shown that the information richness of this assay lends itself to mechanistic analyses, making it possible to differentiate between antibodies which neutralize the same virus but do so via different mechanisms of action.
Key learning objectives
- Discover a more efficient method to screen virus-neutralizing antibodies to accelerate therapeutic antibody discovery
- Learn how to quantitatively evaluate antibody efficacy by IC50 and identify different neutralizing mechanisms of action with the xCELLigence RTCA eSight
- Understand the advantages of combining real-time impedance and live-cell imaging, xCELLigence RTCA eSight assay design and optimization
Who should attend?
- Scientists working in infectious disease, virology, therapeutic antibody research, including lab managers, professors, research scientists, graduate students
For Research Use Only. Not for use in diagnostic procedures.
ACEA Biosciences – A part of Agilent